Levetiracetam LEV CAS 102767-28-2 API Factory USP EP Standard High Purity

Short Description:

Chemical Name: Levetiracetam; LEV

CAS: 102767-28-2

Appearance: White or Almost White Crystals Powder

Assay: 98.0%~102.0%

Third-generation Antiepileptic Drug

API High Quality, Commercial Production

Inquiry: alvin@ruifuchem.com

Send email to us

Product Detail

Product Tags

Description:

Manufacturer Supply with High Purity and Stable Quality
Chemical Name: Levetiracetam
CAS: 102767-28-2
API USP/EP Standard, Commercial Production
Third-generation Antiepileptic Drug

Chemical Properties:

Chemical Name	Levetiracetam
Synonyms	LEV; (S)-2-(2-Oxo-1-pyrrolidinyl)butyramide; UCB-L059
CAS Number	102767-28-2
CAT Number	RF-API61
Stock Status	In Stock, Production Scale Up to Tons
Molecular Formula	C8H14N2O2
Molecular Weight	170.21
Melting Point	116.0-119.0℃
Brand	Ruifu Chemical

Specifications:

Item	Specifications
Appearance	White or Almost White Crystals Powder
Identification IR	The Spectrum abtained from sample consists with that obtained from reference substance
Appearance of Solution	Clear and not more intensely coloured than BY6
Enantiomeric Purity Impurity D	≤0.80%
Water	≤0.50%
Sulfated Ash	≤0.10%
Heavy Metals	≤0.001%
Related Substances
Impurity A	≤0.30%
Any Unspecified Impurity	≤0.05%
Total Unspecified Impurities	≤0.10%
Total Impurities	≤0.40%
Impurity F	≤0.10%
Residual Solvents
Benzene	≤2ppm
Dichloromethane	≤600ppm
Ethyl Acetate	≤5000ppm
Acetone	≤5000ppm
Assay	98.0%~102.0%
Test Standard	USP Standard; EP Standard
Usage	API Third-generation Antiepileptic Drug

Package & Storage:

Package: Bottle, Aluminum foil bag, Cardboard drum, 25kg/Drum, or according to customer's requirement.

Storage Condition: Store in sealed containers at cool and dry place; Protect from light, moisture and pest infestation.

Advantages:

FAQ:

Application:

Levetiracetam (CAS: 102767-28-2), a derivative of pilacetam, is a novel third-generation antiepileptic drug approved by the US FDA in 1999. It was initially used for the adjunctive treatment of partial seizures in adults. In 2005, Levetiracetam was approved in oral tablets and solutions for the adjunctive treatment of partial seizures in children aged 4 years and older. It is mainly used for the additive treatment of partial seizures in adults and children over 4 years old, and can also be used only for partial seizures and systemic seizures in adults. It also has certain curative effect on myoclonic epilepsy in teenagers, refractory epilepsy, absent epilepsy in children and persistent epilepsy.